[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349978-105":59,"doc-detail-349978-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","multiple-omics-analyses-and-experiments-validation-identify-prdx3-as-a-biomarker-of-prognosis-and-antioncogene-in-kidney-clear-cell-carcinoma","Multiple omics analyses and experiments validation identify PRDX3 as a biomarker of prognosis and antioncogene in kidney clear cell carcinoma","","Peroxiredoxin 3 (PRDX3), a mitochondrial redox enzyme, is explored for its tumor initiation roles and potential clinical relevance. A pan-cancer analysis across 33 cancers evaluates PRDX3 expression, gene alterations, mutations, methylation, subcellular localization, signaling pathways, tumor microenvironment, immune infiltration, and links to patient outcomes using TCGA. Functional validation in kidney clear cell carcinoma (KIRC) applies RT-qPCR, Western blotting, and Transwell and scratch assays, showing PRDX3-dependent effects on prognosis and malignant phenotypes. Results suggest a tumor-suppressive role via PPAR signaling.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/multiple-omics-analyses-and-experiments-validation-identify-prdx3-as-a-biomarker-of-prognosis-and-antioncogene-in-kidney-clear-cell-carcinoma/349978/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/multiple-omics-analyses-and-experiments-validation-identify-prdx3-as-a-biomarker-of-prognosis-and-antioncogene-in-kidney-clear-cell-carcinoma/349978.png","ImageObject",300,407,{"name":92,"@type":93},"Margaret","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What data and analyses were used to study PRDX3 across cancers?","Question",{"text":112,"@type":113},"The study performed a systematic pan-cancer analysis across 33 cancers using TCGA, examining PRDX3 expression, gene alterations and mutations, methylation, localization, signaling pathways, tumor microenvironment, immune infiltration, and associations with clinical outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was PRDX3 experimentally validated in kidney clear cell carcinoma (KIRC)?",{"text":117,"@type":113},"In KIRC models, PRDX3 function was validated using RT-qPCR and Western blotting, along with Transwell and scratch assays, to assess malignant phenotypes and related signaling changes.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the proposed clinical implication of PRDX3 based on the results?",{"text":121,"@type":113},"PRDX3 expression is linked to patient prognosis in multiple tumor types, and in KIRC overexpression suppresses malignant phenotypes, suggesting PRDX3 as a potential prognostic biomarker and tumor-suppressive factor.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349978,1790147353,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","OPEN ACCESS  \nCitation: Li Y, Tan X, Li Z, Chen P (2026) Multiple omics analyses and experiments validation identify PRDX3 as a biomarker of prognosis and antioncogene in kidney clear cell carcinoma. PLoS One 21(3): e0345095. [https://](https://)[ ](https://)[doi.org/10.1371/journal.pone.0345095](doi.org/10.1371/journal.pone.0345095)  \nEditor: Xiaoen Wei, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, CHINA  \nReceived: November 13, 2025  \nAccepted: February 27, 2026  \nPublished: March 16, 2026  \nPeer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0345095  \nCopyright: © 2026 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution,  \nRESEARCH ARTICLE  \nMultiple omics analyses and experiments validation identify PRDX3 as a biomarker of prognosis and antioncogene in kidney clear cell carcinoma  \nYanyan Li1, Xiangyuan Tan2, Zhanzhan Li2, Peng Chen3*  \n1 Department of Nursing, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China, 2 Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China, 3 Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China  \n* [chenpengsurgery@hotmail.com](chenpengsurgery@hotmail.com)  \nAbstract  \nPeroxiredoxin 3 (PRDX3), a key mitochondrial redox enzyme, has been implicated in malignant tumor initiation and development. However, the its biological function and clinical relevance remain unclear. Here, we performed a systematic pan-cancer analysis of PRDX3 across 33 cancers using The Cancer Genome Atlas database, examining its expression patterns, gene alterations and mutations, methylation, subcellular localization, signaling pathways, tumor microenvironment, immune infiltration, and associations with clinical outcomes. We further validated the biological function role of PRDX3 in kidney clear cell carcinoma (KIRC) through reverse transcription quantitative polymerase chain reaction, Western blotting, Transwell assays, and scratch assays. PRDX3 was differentially expressed in cancers, and its expression appeared to be influenced by copy number variation and methylation status. PRDX3 levels were significantly associated with patient prognosis in multiple tumor types, suggesting context-dependent roles in tumor biology. Functional analyses indicated that PRDX3 may affect tumor progression through programs related to cell-cycle regulation, metabolism, and redox processes. In KIRC models, PRDX3 overexpression suppressed malignant phenotypes and was accompanied by changes in PPAR signaling pathway. Collectively, our results support PRDX3 as potential prognostic biomarker and suggest a tumor-suppressive role in KIRC, although further mechanistic and in vivo validation is warranted.  \nIntroduction  \nMalignant tumors remain a leading cause of death worldwide [ 1] . In a World Health Organization (WHO) assessment of 183 countries surveyed, cancer ranks first or second among causes of death before the age 70 years in 112 countries and third or fourth in 23 other countries. In 2020, the international Agency for Research on  \nPLOS One | [https://doi.org/10.1371/journal.pone.0345095](https://doi.org/10.1371/journal.pone.0345095) March 16, 2026 1 / 23  \nand reproduction in any medium, provided the original author and source are credited.  \nData availability statement: All relevant data are within the manuscript and its Supporting  Information files.  \nFunding: The author(s) received no specific funding for this work.  \nCompeting interests: The authors have declared that no competing in","cbCaiue1CPwbaPdC","https://ap.wps.com/l/cbCaiue1CPwbaPdC","pdf",6327274,23,"English","# Abstract\n# Introduction\n# Materials and methods\n# Results\n## Pan-cancer bioinformatics findings\n## Experimental validation in KIRC\n# Discussion\n# Conclusion","[{\"question\":\"What data and analyses were used to study PRDX3 across cancers?\",\"answer\":\"The study performed a systematic pan-cancer analysis across 33 cancers using TCGA, examining PRDX3 expression, gene alterations and mutations, methylation, localization, signaling pathways, tumor microenvironment, immune infiltration, and associations with clinical outcomes.\"},{\"question\":\"How was PRDX3 experimentally validated in kidney clear cell carcinoma (KIRC)?\",\"answer\":\"In KIRC models, PRDX3 function was validated using RT-qPCR and Western blotting, along with Transwell and scratch assays, to assess malignant phenotypes and related signaling changes.\"},{\"question\":\"What is the proposed clinical implication of PRDX3 based on the results?\",\"answer\":\"PRDX3 expression is linked to patient prognosis in multiple tumor types, and in KIRC overexpression suppresses malignant phenotypes, suggesting PRDX3 as a potential prognostic biomarker and tumor-suppressive factor.\"}]","Multiple omics analyses and experiments validation identify PRDX3 as a biomarker of prognosis and antioncogene in kidney clear cell carcinoma | PDF",1790086550,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5996ba758cff9cda7f4f4959690ee7fe.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/542b1b85ba2021542c237fd961863533.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ceacdb8739aa625152a994ff377fb965.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc4693294e50c4c09b98631fbebffe8f.webp",980,1268]